Search results for "IMM"

showing 10 items of 18201 documents

Paving the way of systems biology and precision medicine in allergic diseases: the Me DALL success story

2016

MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sen…

0301 basic medicineAllergyeducation.field_of_studybusiness.industrySystems biologyImmunologyPopulationAtopic dermatitisOmicsmedicine.diseasePrecision medicine3. Good healthReview article03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemImmunologyImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionbusinesseducationmedia_commonAllergy
researchProduct

Cellular and Molecular Heterogeneity Associated with Vessel Formation Processes

2018

The microvasculature heterogeneity is a complex subject in vascular biology. The difficulty of building a dynamic and interactive view among the microenvironments, the cellular and molecular heterogeneities, and the basic aspects of the vessel formation processes make the available knowledge largely fragmented. The neovascularisation processes, termed vasculogenesis, angiogenesis, arteriogenesis, and lymphangiogenesis, are important to the formation and proper functioning of organs and tissues both in the embryo and the postnatal period. These processes are intrinsically related to microvascular cells, such as endothelial and mural cells. These cells are able to adjust their activities in r…

0301 basic medicineAngiogenesisNeovascularization Physiologiclcsh:MedicineReview ArticleBiologyMolecular heterogeneityGeneral Biochemistry Genetics and Molecular BiologyMural cell03 medical and health sciences0302 clinical medicineVasculogenesisAnimalsHumansGeneral Immunology and Microbiologylcsh:RVascular biologyGeneral MedicineLymphangiogenesis030104 developmental biologyOrgan Specificity030220 oncology & carcinogenesisBlood VesselsArteriogenesisNeuroscienceSignal TransductionBioMed Research International
researchProduct

Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer

2019

Background:Vascular endothelial growth factor (VEGF)-C, -D, and VEGF receptor-3 are proteins characterized as crucial for tumor lymphangiogenesis. It is accompanied by angiogenesis during wound healing, but also in the neoplastic process. The research studies have shown that the lymphatic system plays a key role in the progression of carcinogenesis.Objective:The aim of this study was to evaluate changes in the expression of VEGF-C, VEGF-D and VEGFR-3 in different grades of endometrial cancer (G1-G3).Methods:The study included 45 patients diagnosed with endometrial cancer (G1=17; G2=15; G3=13) and 15 patients without neoplastic changes. The expression of VEGF-C, VEGF-D, and VEGFR-3 was asses…

0301 basic medicineAngiogenesisVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVEGF-CPharmaceutical ScienceVEGF-Dmedicine.disease_causeMetastasisTranscriptome03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansANOVANeovascularization Pathologicbusiness.industryEndometrial cancerCancerVascular Endothelial Growth Factor Receptor-3medicine.diseaseImmunohistochemistryEndometrial NeoplasmsLymphangiogenesisVEGFR-3lymphangiogenesisVascular endothelial growth factor030104 developmental biologychemistry030220 oncology & carcinogenesisendometrial cancerCancer researchFemaleNeoplasm GradingCarcinogenesisbusinessBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

2017

Thymoquinone (TQ), the main bioactive component of Nigella sativa, has been found to exhibit anticancer effects in numerous preclinical studies. Due to its multitargeting nature, TQ interferes in a wide range of tumorigenic processes and counteracts carcinogenesis, malignant growth, invasion, migration, and angiogenesis. Moreover, TQ can specifically sensitize tumor cells toward conventional cancer treatments (e.g., radiotherapy, chemotherapy, and immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review, we summarized the adjuvant potential of TQ as observed in various in vitro and in vivo animal models and discussed the pharmacological pro…

0301 basic medicineAngiogenesismedicine.medical_treatmentthymoquinoneReviewPharmacologycancer treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdjuvant therapyMedicinePharmacology (medical)preclinical studiesThymoquinonePharmacologyChemotherapybusiness.industrylcsh:RM1-950Canceradjuvant therapyImmunotherapymedicine.diseaseRadiation therapylcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisCancer researchbusinessAdjuvantFrontiers in Pharmacology
researchProduct

Subclinical gut inflammation in ankylosing spondylitis

2015

Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic…

0301 basic medicineAnkylosing spondylitis; Gut inflammation; Innate lymphoid cells; Interleukin-17; Interleukin-23; Adaptive Immunity; Animals; Cytokines; Disease Models Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity Innate; Inflammation; Inflammatory Bowel Diseases; Intestines; Macrophages; Mice; Spondylitis Ankylosing; Rheumatology; Medicine (all)MacrophageAdaptive ImmunityInterleukin-23Inflammatory bowel diseaseGastroenterologyMiceInterleukin 23InnateMedicineSubclinical infectionMedicine (all)Interleukin-17digestive oral and skin physiologyInnate lymphoid cellIntestineIntestinesCytokinesmedicine.symptomHumanAnkylosingmedicine.medical_specialtyDisease ModelInflammationdigestive system03 medical and health sciencesRheumatologyInternal medicineInnate lymphoid cellAnimalsHumansSpondylitis AnkylosingCytokineSpondylitisGut inflammationSpondylitiInflammationAnkylosing spondylitisAnimalbusiness.industryMacrophagesInflammatory Bowel DiseaseImmunityInflammatory Bowel Diseasesmedicine.diseaseImmunity InnateDysbiosiGastrointestinal MicrobiomeAnkylosing spondylitiDisease Models Animal030104 developmental biologyDysbiosisbusinessDysbiosisCurrent Opinion in Rheumatology
researchProduct

Tenofovir-induced toxicity in renal proximal tubular epithelial cells

2017

OBJECTIVE In-vivo studies suggest that mitochondria is involved in tenofovir (TFV)-induced renal toxicity, but the underlying mechanisms are still unclear. The aim of the present study was to assess the effects of TFV and its prodrug, TFV disoproxil fumarate, on mitochondrial function and cell survival/viability in a renal proximal tubular cell line. DESIGN AND METHODS We evaluated parameters of cellular proliferation/survival (cell count, cell cycle, viability) and mitochondrial function (oxygen consumption, mitochondrial membrane potential, reactive oxygen species production) in NRK-52E cells. Intracellular TFV was measured by HPLC and expression of antioxidant genes was analysed by real-…

0301 basic medicineAnti-HIV AgentsCell Survival030106 microbiologyImmunologyCellOxidative phosphorylationMitochondrionPharmacologyCell Line03 medical and health sciencesmedicineHumansImmunology and AllergyTenofovirCell Proliferationchemistry.chemical_classificationKidneyReactive oxygen speciesCell growthEpithelial Cellsmedicine.diseaseMitochondriaMitochondrial toxicity030104 developmental biologyInfectious Diseasesmedicine.anatomical_structurechemistryIntracellularAIDS
researchProduct

Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines

2019

T cells are key effectors of anticancer immunity. They are capable of distinguishing tumor cells from normal ones by recognizing major histocompatibility complex–bound cancer-specific peptides. Accumulating evidence suggests that peptides associated with T cell–mediated tumor rejection arise predominantly from somatically mutated proteins and are unique to every patient's tumor. Knowledge of an individual's cancer mutanome (the entirety of cancer mutations) allows harnessing this enormous tumor cell–specific repertoire of highly immunogenic antigens for individualized cancer vaccines. This review outlines the preclinical and clinical state of individualized cancer vaccine development and t…

0301 basic medicineAnticancer immunityT-Lymphocytesmedicine.medical_treatmentTumor cellsCancer VaccinesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAntigens NeoplasmNeoplasmsAnimalsHumansMedicineMolecular Targeted TherapyPrecision Medicinebusiness.industryEffectorCancerGeneral MedicineImmunotherapymedicine.diseaseTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisMutationCancer researchImmunotherapybusinessForecastingMajor histocompatibilityAnnual Review of Medicine
researchProduct

Numerous Fasciola plasminogen-binding proteins may underlie blood-brain barrier leakage and explain neurological disorder complexity and heterogeneit…

2019

15 páginas, 5 figuras y 1 tabla

0301 basic medicineAntifibrinolyticContact systemmedicine.drug_classmedicine.medical_treatment030231 tropical medicineBradykininInflammationNeurological disorderFibrinolysis systemProteomic and mass spectrometry analysesBlood–brain barrierFasciola excretome/secretomeProinflammatory cytokine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood-brain barrier leakageFibrinolysismedicineIndicators and preventionAcute and chronic phasesPlasminogen-binding proteinsFasciolabiologyHuman fascioliasis030108 mycology & parasitologymedicine.diseasebiology.organism_classificationInfectious Diseasesmedicine.anatomical_structurechemistryImmunologyAnimal Science and ZoologyParasitologymedicine.symptomNeurological disordersResearch Article
researchProduct

Aspergilosis invasora en el paciente con enfermedad oncohematológica

2018

Invasive aspergillosis is the most common invasive fungal infection in patients with acute hematological malignancies or treated with hematopoietic stem cell transplantation due to the marked alteration of the physiological mechanisms of antifungal immunity that takes place in these situations. For this reason, antifungal prophylaxis has a relevant role in these patients. The introduction of new antifungal agents has motivated the updating of recommendations for prophylaxis and treatment in different guidelines. The objectives of this chapter are a brief review of the mechanisms of immunity against fungi, the definition of risk for developing an invasive fungal infection and an update of th…

0301 basic medicineAntifungalmedicine.drug_classbusiness.industrymedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantationAspergillosismedicine.diseaseMicrobiology03 medical and health sciencesInfectious DiseasesHematological DiseasesImmunityImmunologymedicineIn patientbusinessRevista Iberoamericana de Micología
researchProduct

Dying with or because of invasive fungal infection? The role of immunity exhaustion on patient outcome

2016

De Rosa et al. considered clinical scores, biomarkers and their combination as useful aids for an early antifungal treatment and advocated the adoption of de-escalation therapy in an antifungal stewardship approach as a possible key for a better management of these patients. Authors considered the high burden of invasive fungal infections in terms of patient outcomes and costs and focused on current strategies for their optimization.

0301 basic medicineAntifungalmedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain Medicinebusiness.industrymedicine.drug_class030106 microbiology030208 emergency & critical care medicinemedicine.diseasesepsis fungal infectionOutcome (game theory)03 medical and health sciences0302 clinical medicineAnesthesiology and Pain MedicineAcquired immunodeficiency syndrome (AIDS)ImmunityAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE Second RoundEmergency MedicineMedicineMED/41 - ANESTESIOLOGIAbusinessIntensive care medicine
researchProduct